QQQ   444.74 (-0.02%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   906.12 (+0.40%)
NIO   4.62 (-1.07%)
AMD   181.89 (+1.28%)
BABA   72.41 (+1.15%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.95 (-2.87%)
DIS   122.35 (+1.13%)
AMC   3.78 (-12.90%)
PFE   27.87 (+0.32%)
PYPL   67.14 (+0.86%)
XOM   115.64 (+0.58%)
QQQ   444.74 (-0.02%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   906.12 (+0.40%)
NIO   4.62 (-1.07%)
AMD   181.89 (+1.28%)
BABA   72.41 (+1.15%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.95 (-2.87%)
DIS   122.35 (+1.13%)
AMC   3.78 (-12.90%)
PFE   27.87 (+0.32%)
PYPL   67.14 (+0.86%)
XOM   115.64 (+0.58%)
QQQ   444.74 (-0.02%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   906.12 (+0.40%)
NIO   4.62 (-1.07%)
AMD   181.89 (+1.28%)
BABA   72.41 (+1.15%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.95 (-2.87%)
DIS   122.35 (+1.13%)
AMC   3.78 (-12.90%)
PFE   27.87 (+0.32%)
PYPL   67.14 (+0.86%)
XOM   115.64 (+0.58%)
QQQ   444.74 (-0.02%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   906.12 (+0.40%)
NIO   4.62 (-1.07%)
AMD   181.89 (+1.28%)
BABA   72.41 (+1.15%)
T   17.57 (+0.11%)
F   13.22 (+1.23%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.95 (-2.87%)
DIS   122.35 (+1.13%)
AMC   3.78 (-12.90%)
PFE   27.87 (+0.32%)
PYPL   67.14 (+0.86%)
XOM   115.64 (+0.58%)
NASDAQ:ASMB

Assembly Biosciences (ASMB) Stock Price, News & Analysis

$13.02
-0.36 (-2.69%)
(As of 11:02 AM ET)
Today's Range
$13.02
$13.20
50-Day Range
$9.60
$13.58
52-Week Range
$7.69
$20.04
Volume
12,020 shs
Average Volume
29,393 shs
Market Capitalization
$71.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Assembly Biosciences MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.71
Upright™ Environmental Score
News Sentiment
0.02mentions of Assembly Biosciences in the last 14 days
Based on 26 Articles This Week
Insider Trading
Acquiring Shares
$233,991 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($14.29) to ($14.77) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.34 out of 5 stars

Medical Sector

753rd out of 939 stocks

Pharmaceutical Preparations Industry

346th out of 433 stocks

ASMB stock logo

About Assembly Biosciences Stock (NASDAQ:ASMB)

Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research, as well as a partnership with Gilead Sciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

ASMB Stock Price History

ASMB Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Libby Assembly of God Church hosting noted author
See More Headlines
Receive ASMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ASMB
CUSIP
92282210
Employees
68
Year Founded
2005

Profitability

Net Income
$-93,090,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.25 million
Book Value
$20.34 per share

Miscellaneous

Free Float
5,256,000
Market Cap
$73.32 million
Optionable
Optionable
Beta
0.56

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Jason A. Okazaki (Age 48)
    CEO, President & Director
    Comp: $869.28k
  • Dr. William E. Delaney IV (Age 52)
    Ph.D., Chief Scientific Officer
    Comp: $664.4k
  • Dr. Uri A. Lopatin M.D. (Age 52)
    Co-Founder and Clinical & Scientific Advisor
    Comp: $608.55k
  • Dr. Adam Zlotnick
    Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board
  • Jeanette M Bjorkquist
    Executive Director of Accounting & Treasury
  • Shannon Ryan
    Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management
  • Ms. Jennifer A. Troia MHROD
    SHRM-SCP, SPHR, Chief Human Resources Officer
  • Dr. Nicole S. White Ph.D.
    Chief Manufacturing Officer
  • Dr. Anuj Gaggar M.D.
    Ph.D., Chief Medical Officer
  • Mr. Thomas E. Rollins (Age 68)
    Executive Officer
    Comp: $472.55k

ASMB Stock Analysis - Frequently Asked Questions

How have ASMB shares performed in 2024?

Assembly Biosciences' stock was trading at $9.8412 at the beginning of 2024. Since then, ASMB shares have increased by 34.1% and is now trading at $13.20.
View the best growth stocks for 2024 here
.

Are investors shorting Assembly Biosciences?

Assembly Biosciences saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 60,200 shares, an increase of 207.1% from the February 29th total of 19,600 shares. Based on an average daily volume of 29,900 shares, the days-to-cover ratio is presently 2.0 days. Approximately 1.6% of the shares of the stock are short sold.
View Assembly Biosciences' Short Interest
.

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences, Inc. (NASDAQ:ASMB) announced its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($4.92) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($6.84) by $1.92. The biopharmaceutical company had revenue of $6.25 million for the quarter.

When did Assembly Biosciences' stock split?

Assembly Biosciences shares reverse split on Monday, February 12th 2024. The 1-12 reverse split was announced on Monday, February 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is John McHutchison's approval rating as Assembly Biosciences' CEO?

8 employees have rated Assembly Biosciences Chief Executive Officer John McHutchison on Glassdoor.com. John McHutchison has an approval rating of 80% among the company's employees. 76.0% of employees surveyed would recommend working at Assembly Biosciences to a friend.

What other stocks do shareholders of Assembly Biosciences own?
Who are Assembly Biosciences' major shareholders?

Assembly Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (42.68%), Vanguard Group Inc. (42.68%), Federated Hermes Inc. (0.46%), Acuitas Investments LLC (0.40%), Northern Trust Corp (0.20%) and Marquette Asset Management LLC (0.08%). Insiders that own company stock include Alexander Schornstein, Jason A Okazaki, Jeanette M Bjorkquist, John G Mchutchison, Luisa M Stamm, Michael P Samar, Nicole S White, Timothy A Springer, William E Iv Delaney and William E Iv Delaney.
View institutional ownership trends
.

How do I buy shares of Assembly Biosciences?

Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ASMB) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners